[
  {
    "ticker": "AFP",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975666",
    "id": "02975666",
    "pages": 2,
    "price_sensitive": false,
    "date": "20250801",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mdwwc2rtwrgv.pdf",
    "summary": "<h3>Summary of Material Information:</h3>\n<ul>\n<li><strong>FY26 Guidance</strong>: Confirmed operating profit forecast of <strong>$20.0\u2013$24.0 million</strong>.  </li>\n<li><strong>FY27 Target</strong>: Revenue goal of <strong>$300 million</strong>, with progress on track.  </li>\n<li><strong>R&amp;D Pipeline</strong>: Targeting <strong>$8+ billion addressable markets</strong>; includes 8 patented products, 24 off-patent injectables, and an improved migraine treatment.  </li>\n<li><strong>Commercialization Programs</strong>: Five advanced R&amp;D projects entering global markets:  </li>\n<li>Multiple Maxigesic\u00ae dose forms  </li>\n<li>Crystaderm\u00ae (anti-bacterial)  </li>\n<li>Micolette\u00ae (bowel obstruction)  </li>\n<li>Kiwisoothe\u00ae (tablets/sachets)  </li>\n<li>Capsaicin cream (osteoarthritis/neuropathic pain).  </li>\n</ul>\n<p><em>(No material capital markets or trading actions announced.)</em></p>",
    "usage": {
      "prompt_tokens": 1072,
      "completion_tokens": 184,
      "total_tokens": 1256,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-07-31T21:53:11.101946"
  },
  {
    "ticker": "AFP",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975667",
    "id": "02975667",
    "pages": 4,
    "price_sensitive": false,
    "date": "20250801",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mdwygggfj5k9.pdf",
    "summary": "<ul>\n<li><strong>Annual revenue milestone</strong>: Achieved $208M in sales (first time &gt;$200M), with Australasia contributing $181M.  </li>\n<li><strong>North American expansion</strong>: Launched Maxigesic IV/tablet (Combogesic) in US and Canada (addressable market &gt;US$8B); restructured US distribution.  </li>\n<li><strong>Product pipeline</strong>: 8 patented products in R&amp;D, 24 off-patent injectables, and 5 advanced programs (e.g., Crystaderm, capsaicin cream).  </li>\n<li><strong>Financials</strong>: Net debt reduced to $14.5M (from $16.2M); dividend increased to 1.8 cps (from 1.6 cps).  </li>\n<li><strong>FY27 target</strong>: Ambitious $300M revenue goal.  </li>\n</ul>\n<p><em>No material trading/capital markets actions identified (e.g., no capital raising or halt).</em></p>",
    "usage": {
      "prompt_tokens": 1984,
      "completion_tokens": 190,
      "total_tokens": 2174,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-07-31T21:54:02.556147"
  },
  {
    "ticker": "AFP",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975668",
    "id": "02975668",
    "pages": 30,
    "price_sensitive": false,
    "date": "20250801",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mdx0kbh3x5mq.pdf",
    "summary": "<h3><strong>Material Information Summary (AFT Pharmaceuticals \u2013 Annual Shareholders\u2019 Meeting Presentation)</strong></h3>\n<p><strong>Financial &amp; Operational Highlights:</strong><br />\n- <strong>FY25 Revenue</strong>: NZ$208.0M (5-year CAGR: 14%).<br />\n- <strong>FY25 Operating Profit</strong>: NZ$17.6M (down from NZ$24.2M in FY24), impacted by lower license income (NZ$0.7M vs. NZ$8.5M) and strategic investments.<br />\n- <strong>Dividend</strong>: Increased to 1.8cps (FY24: 1.6cps).<br />\n- <strong>Net Debt</strong>: NZ$14.5M (down from NZ$16.2M in FY24).<br />\n- <strong>Cash Position</strong>: Closing balance not disclosed (refer to Appendix 4C for details).  </p>\n<p><strong>Growth Targets:</strong><br />\n- <strong>FY27 Revenue Target</strong>: NZ$300M.<br />\n- <strong>FY26 Operating Profit Guidance</strong>: NZ$20M\u2013NZ$24M.  </p>\n<p><strong>Key Developments:</strong><br />\n1. <strong>Geographic Expansion</strong>:<br />\n   - Products now sold in <strong>80 countries</strong> (Maxigesic in 73 markets).<br />\n   - New subsidiaries in <strong>USA, UK, EU, Canada, South Africa, Hong Kong, and Singapore</strong> approaching breakeven.<br />\n2. <strong>R&amp;D Pipeline</strong>:<br />\n   - <strong>8 patented products</strong> in development, including Maxigesic variants (IV, pediatric, rapid-dose), Crystaderm (antibacterial), and Pascomer (rare disease).<br />\n   - <strong>24+ injectable generics</strong> under development via Sinoject JV (AFT 70%).<br />\n3. <strong>Capital Structure</strong>:<br />\n   - No new capital raising announced.<br />\n   - Equity grew steadily since FY19; net debt/equity ratio declined.  </p>\n<p><strong>Governance</strong>:<br />\n- Re-election of <strong>Dr Hartley Atkinson</strong> and election of <strong>Allison Yorston</strong> to the board.  </p>\n<p><strong>Other Material Points</strong>:<br />\n- <strong>Risk Factors</strong>: Dependence on international expansion execution and R&amp;D commercialization.<br />\n- <strong>No material M&amp;A or asset divestments disclosed</strong>.  </p>\n<p><strong>Format Note</strong>: Excludes routine operational updates, director bios, and forward-looking disclaimers.  </p>\n<p><strong>Actionable Data for Traders</strong>: Monitor FY26 revenue trajectory (+6% YoY target) and NZD liquidity impacts from global subsidiary ramp-up.  </p>\n<hr />\n<p><strong>Brevity Key</strong>: Focused on valuation drivers (revenue growth, debt, dividends), liquidity (geographic expansion), and capital structure (no dilution).</p>",
    "usage": {
      "prompt_tokens": 5861,
      "completion_tokens": 528,
      "total_tokens": 6389,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-07-31T21:53:52.852832"
  }
]